| 2.2 0.17 (8.37%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.92 | 1-year : | 3.73 |
| Resists | First : | 2.5 | Second : | 3.2 |
| Pivot price | 1.98 |
|||
| Supports | First : | 1.37 | Second : | 1.14 |
| MAs | MA(5) : | 2.11 |
MA(20) : | 1.98 |
| MA(100) : | 4.45  |
MA(250) : | 7.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 40.1 |
D(3) : | 38.8 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 17.04 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NAYA ] has closed below upper band by 37.9%. Bollinger Bands are 74% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.48 - 2.49 | 2.49 - 2.5 |
| Low: | 2.11 - 2.12 | 2.12 - 2.13 |
| Close: | 2.14 - 2.16 | 2.16 - 2.17 |
INVO Bioscience is a medical device company providing devices and products for infertility diagnosis. Its flagship product is INVOcell, a reproductive technology that allows fertilization and early embryo development to take place within the woman’s body.
Wed, 30 Apr 2025
INVO Fertility Stock Is Surging Wednesday: What's Going On? - INVO Fertility (NASDAQ:IVF) - Benzinga
Mon, 28 Apr 2025
INVO Fertility, Inc. will Change its Ticker to IVF from NAYA - marketscreener.com
Sat, 26 Apr 2025
Sarasota fertility company changes name, ticker symbol - Business Observer
Tue, 15 Apr 2025
NAYA Biosciences spins off cancer drug business 6 months after INVO merger - Fierce Biotech
Mon, 14 Apr 2025
NAYA Biosciences to separate fertility and oncology businesses into distinct operations, changes name to INVO Fertility - MSN
Mon, 14 Apr 2025
NAYA Biosciences shareholders elect board, ratify accountants - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 13.8 (%) |
| Held by Institutions | 16.3 (%) |
| Shares Short | 32 (K) |
| Shares Short P.Month | 8 (K) |
| EPS | -12.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -46.89 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.18 |
| PEG Ratio | 0 |
| Price to Book value | -0.05 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|